ReviewScience advances2019
Current status of opioid addiction treatment and related preclinical research.
Review in Science advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05588726 (Behavioral Intervention to Improve Insomnia Symptoms in Patients With Opioid Use Disorder), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Behavioral Intervention to Improve Insomnia Symptoms in Patients With Opioid Use Disorder
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- Virtual Reality in Prevention and Treatment of Substance-Related Disorders: A Systematic Review of Randomized Controlled Trials.Clinical psychology & psychotherapyPooled it
- Treatment of Moderate-to-Severe Pain in Hepatocellular Carcinoma with Transcutaneous Electrical Acupoint Stimulation: A Randomized Controlled Trial.Journal of pain research · 2024Trial
- Article
- Brixadi for Stimulant Use Disorder: Evolving Pharmacologic Considerations and Clinical Implications.Advances in therapy · 2026Review
- The quantitative economon model as a novel computational tool for addiction research.Experimental and clinical psychopharmacology · 2026Article
- Changes in Blood DNA CpG Methylation Levels in Response to Methadone Maintenance Treatment: Epigenome-Wide Longitudinal Study.Epigenomes · 2026Article
- Reviving the Fight against Opioid Overdoses: Unleashing the Power of Metal-Organic Frameworks for Morphine Removal.ACS applied materials & interfaces · 2025Article
- The neural circuits and signalling pathways of opioid use disorder.Nature reviews. Neuroscience · 2025Review
- Peripheral Blood Cytokines as Markers of Longitudinal Change in White Matter Microstructure Following Inpatient Treatment for Opioid Use Disorders.Biological psychiatry global open science · 2025Article
- Expecting medication misuse: a proactive approach to drug discovery to prevent fatal overdose.Future medicinal chemistry · 2025Review
- A pH-sensitive opioid does not exhibit analgesic tolerance in a mouse model of colonic inflammation.British journal of pharmacology · 2025Article
- Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative outpatient clinic data.Drug and alcohol dependence · 2025Observational
- Effects of intravenous propofol combined with opioids on euphoria in patients undergoing painless gastrointestinal endoscopy: protocol for a randomized double-blind placebo-controlled trial.Frontiers in pharmacology · 2025Article
- Impact of opioid abuse on oral health: a retrospective cohort study.Frontiers in oral health · 2025Article
- iTRAQ proteomic analysis of the anterior insula in morphine-induced conditioned place preference rats with high-frequency deep brain stimulation intervention.Addiction biology · 2025Article
- Serum cytokines and inflammatory proteins in individuals with heroin use disorder: potential mechanistically based biomarkers for diagnosis.Translational psychiatry · 2024Article
- Sex disparities in outcome of medication-assisted therapy of opioid use disorder: Nationally representative study.medRxiv : the preprint server for health sciences · 2024Article
- Evaluating preferences for medication formulation and treatment model among people who use opioids non-medically: A web-based cross-sectional study.Journal of substance use and addiction treatment · 2024Article
- Molecular mechanisms of morphine tolerance and dependence; novel insights and future perspectives.Molecular and cellular biochemistry · 2024Review
- Sex and genetic background influence intravenous oxycodone self-administration in the hybrid rat diversity panel.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Opioid use disorders (OUDs) are diseases of the brain with behavioral, psychological, neurobiological, and medical manifestations. Vulnerability to OUDs can be affected by factors such as genetic background, environment, stress, and prolonged exposure to μ-opioid agonists for analgesia. Two standard-of-care maintenance medications, methadone and buprenorphine-naloxone, have a long-term positive influence on health of persons with opioid addiction. Buprenorphine and another medication, naltrexone, have also been approved for administration as monthly depot injections. However, neither medication is used as widely as needed, due largely to stigma, insufficient medical education or training, inadequate resources, and inadequate access to treatment. Ongoing directions in the field include (i) personalized approaches leveraging genetic factors for prediction of OUD vulnerability and prognosis, or for targeted pharmacotherapy, and (ii) development of novel analgesic medicines with new neurobiological targets with reduced abuse potential, reduced toxicity, and improved effectiveness, especially for chronic pain states other than cancer pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.